On October 9, 2025, Acurx Pharmaceuticals announced that the Australian Patent Office granted a new patent covering DNA Polymerase IIIC inhibitors, expanding its global intellectual‑property portfolio. The patent protects compositions of matter for the ACX‑375C program, adding to the company’s existing U.S., Israeli, Japanese, and Indian patents and extending protection through 2039. This grant strengthens Acurx’s position as it develops oral and parenteral candidates for a range of Gram‑positive infections.
The new Australian patent is part of a broader strategy to secure intellectual property for compounds targeting multidrug‑resistant Gram‑positive pathogens, including MRSA, VRE, PRSP, and B. anthracis. Executive Chairman Robert J. DeLuccia emphasized that the patent strengthens Acurx’s position as it develops oral and parenteral candidates for acute bacterial skin and skin‑structure infections, community‑acquired pneumonia, and inhalational anthrax. The company’s lead candidate, ibezapolstat, remains Phase 3‑ready for Clostridioides difficile infection.
By adding Australia to its list of protected jurisdictions, Acurx enhances its competitive moat and safeguards its pipeline against generic competition. The patent grant supports the company’s long‑term strategy to bring innovative antibiotics to market and to secure exclusive rights in key regions. This milestone reinforces investor confidence in Acurx’s ability to protect and commercialize its novel antibiotic platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.